Novartis gene therapy set to enhance SMA treatment
OAV101 IT expands potential for type II SMA patients Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) achieved the primary endpoint in a phase 3 STEER study. This success could broaden the eligible …